Prepping for HRSA Audits

SPONSORED CONTENT

Are you truly ready for a HRSA audit? Today we have two 340B experts, Dennis Killian and Heather Erickson, from CPS Solutions, LLC. (CPS) here to discuss three topics that will help you prepare. CPS has managed 340B Programs for hospitals and health systems since the program’s inception, ensuring compliance with the 340B statute, HRSA guidance, as well as best practices from across the industry.

The following is a transcript of the above video:

Dennis Killian: Hi, everybody. My name is Dennis Killian. I’m a pharmacist with the CPS Solutions, LLC. (CPS) 340B team, and I work with a lot of covered entities across the nation. We help them with a variety of different services, whether it’s compliance monitoring or to help them optimize their program, basically whatever they need.

Heather

Read More »

RxStrategies

Q: Tell us some interesting details about your company’s history.

Imagine a world where flip phones were the pinnacle of consumer technology – that’s the era when RxStrategies was founded.

Read More »

Unlocking the Value of 340B Consultants: Their Roles and Responsibilities

SPONSORED CONTENT

In the complex landscape of healthcare, the 340B program plays a vital role in ensuring that vulnerable patients with limited financial resources have access to affordable medications. It enables qualified covered entities to maximize their resources and offer a wider range of benefits and services to those in need.

Managing this program efficiently and ensuring compliance with its myriad rules and regulations is a challenging task. This is where 340B consultants step in, serving as invaluable guides and experts. In this article, we will delve into the roles and responsibilities of a 340B consultant.

The Roles of a 340B Consultant

A 340B consultant is a professional who specializes in the 340B program. Their role is multifaceted and encompasses various responsibilities, all aimed at helping providers optimize the benefits of the program while maintaining compliance. Here’s a closer look at their roles:

  1. Program Assessment: One of the primary responsibilities of a 340B consultant is
Read More »

340B Webinar—State of 340B in 2024: Biggest Developments Expected this Year

SPONSORED CONTENT

Join our webinar for a comprehensive exploration of the current status of the 340B program, featuring a review of major industry trends from 2023 and key developments anticipated for 2024.
We’ll discuss what entities should expect and prepare for in the upcoming year, addressing crucial questions about manufacturer restrictions and potential Congressional actions.


Key Points from the 2023 Year in Review:

  • Manufacturer Restrictions: A review of the past year’s events and their current impact on the 340B Program participants.
  • HRSA’s Enhanced Authority: Notably, four entities were removed from the 340B Program, signaling a more assertive approach by HRSA.
  • Leadership Change at OPA: We’ll examine the potential impact of the change in leadership at the Office of Pharmacy Affairs on the program.

Upcoming Challenges:

  • Federal Appeals Court Opinions: Stay tuned for anticipated opinions from two federal appeals courts that could significantly impact the program.
  • Genesis v. HRSA Patient Definition Battle: Explore
Read More »

Visante’s Top 10 Issues Facing Health System Pharmacy for 2024

SPONSORED CONTENT

 In 2024, pharmacy will play an even more significant and critical role in health systems’ financial and operational performance nationwide. While health systems face daunting challenges, increasing risks, and suffocating regulatory and compliance burdens, high-performing pharmacy organizations are poised to mitigate financial losses and improve operations. We’ve never been more bullish about the opportunities for engaged pharmacy executives and leaders in the years ahead.

Skyrocketing drug costs, 340B challenges, growing demands on a shrinking workforce, and the leakage of infusion services and associated financial losses are a few of the challenges we discuss here. But with challenges come opportunities, and in this edition of Visante’s Top 10, we’re pleased to offer exciting and timely solutions that health systems can take advantage of in 2024 and beyond.

Here are our picks for the Top 10 challenges for 2024. To see Visante’s full article including recommendations for tackling these

Read More »

Exploring Key Aspects of the 340B Program

SPONSORED CONTENT

The 340B drug pricing program allows covered entities serving vulnerable patient populations to buy medications at a discount. Since 1987, AIDS Healthcare Foundation has been on the frontline of the HIV response in the United States.  AHF cares for patients regardless of their ability to pay.  For AHF, 340B savings offset the costs of the critical services it provides to people living with HIV.

The 340B program transforms the healthcare landscape by leveling the playing field so providers can more effectively serve vulnerable communities. When individuals have access to affordable healthcare, they are more likely to seek necessary treatment and preventive services. 

We will explore some key aspects of the 340B program with AHF Assistant Director of Prevention Jomil Luna. As a steadfast supporter of the 340B program, Jomil is a passionate public health and LGBTQ advocate in the New York community. He received his Master’s in Public Health from Rutgers University,

Read More »

Implementing for Success

SPONSORED CONTENT

After 30 years of serving vulnerable populations, the 340B Drug Pricing Program has grown considerably in scale and complexity. While it is arguably one of the most successful public/private partnerships in healthcare history, 340B is facing policy obstacles and headwinds that can make administering a program more challenging for covered entities than ever. This includes manufacturers limiting discounts to a single contract pharmacy and excluding high-cost drugs from the program. 340B administration is also complicated by perennial regulatory updates from CMS that impact the program directly and indirectly.

For these reasons and more, it can often make sense for covered entities to seek the expertise and assistance of a 340B vendor to reduce the complexity and optimize the savings from 340B.  When you are working with partners, it’s important to ensure you are setting yourself up for success and the greatest return on your investment from the start. The implementation and onboarding process

Read More »

Unlocking Greater 340B Savings

SPONSORED CONTENT

The 340B program serves as a lifeline for many communities, allowing them to provide critical services to vulnerable, underserved patients. But unfortunately, the industry faces a spectrum of challenges, from mounting drug manufacturer restrictions to incomplete referral claims capture, which hinder a covered entity’s ability to optimize their 340B program.

To help covered entities broaden the reach of their 340B program, SUNRx, a leading 340B technology solutions company, recently acquired AuthorityRx, including the automated Advanced Claims Capture (ACC) solution. By combining the technology and expertise of the companies, SUNRx is able to provide entities greater resources to serve patients and communities.

Today, when a patient of a 340B entity visits a referral provider, the entity often loses the potential savings associated with their 340B program. In the past, identifying referral claims and other missed claims with traditional referral capture models has been a complex, often manual process that results

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report